Quant Large and Mid Cap Fund
The scheme seeks to provide capital appreciation by investing in a portfolio of Large and Midcap companies.
Growthvine rating: 3/5 — ranked #16 of 41 in category.
Fund basics
| Category | Equity: Large & Mid Cap |
|---|
| NAV | ₹119.28 (as of 2026-10-01) |
|---|
| AUM | ₹3,496 Cr |
|---|
| Expense ratio | 1.65% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ayusha Kumbhat |
|---|
| Exit load | 1% for redemption within 15 days |
|---|
Performance & risk
| 5-year annualised return | 13.29% |
|---|
| Sharpe ratio | 0.54 |
|---|
| Standard deviation | 19.47% |
|---|
| Max drawdown | −53.45% |
|---|
| Alpha | 2.18 |
|---|
| Beta | 1.17 |
|---|
Over 5 years, captured 111.2% of NIFTY LargeMidcap 250's upside and 101.5% of its downside.
Market cap allocation
| Large cap | 45.5% |
|---|
| Mid cap | 46.8% |
|---|
| Small cap | 7.7% |
|---|
Concentration
| Top 5 holdings | 39.0% |
|---|
| Top 10 holdings | 62.3% |
|---|
| Total holdings | 28 |
|---|
| Index overlap | 4.7% |
|---|
| Active share | 95.3% |
|---|
Top holdings
- TREPS 01-Sep-2026 DEPO 10 — 21.3%
- Aurobindo Pharma Ltd. — 9.7%
- Lloyds Metals and Energy Limited — 9.0%
- Samvardhana Motherson International Limited — 8.1%
- Adani Enterprises Ltd. — 6.4%
- Adani Green Energy Limited — 5.7%
- Bharti Airtel Limited 29/09/2026 — 5.5%
- Adani Power Limited — 5.2%
- Bharat Heavy Electricals Ltd. — 4.6%
- Glenmark Pharmaceuticals Ltd 29/09/2026 — 4.1%
Top sectors
- Derivatives — 26.1%
- Energy — 12.6%
- Pharma & Biotech — 12.0%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 4.2% | Q1 (Top) | #3 of 38 |
| 2025 | −2.0% | Q4 (Bottom) | #32 of 34 |
| 2024 | 17.8% | Q3 | #21 of 29 |
| 2023 | 32.2% | Q1 (Top) | #7 of 28 |
| 2022 | 13.0% | Q1 (Top) | #1 of 28 |